A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects

NCT05503693 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: AP303 50 μg
DRUG: AP303 150 μg
DRUG: AP303 300 μg
DRUG: AP303 600 μg
DRUG: Placebo 50 μg
DRUG: Placebo 150 μg
DRUG: Placebo 300 μg
DRUG: Placebo 600 μg

Sponsor

Alebund Pty Ltd